Placebo to Romosozumab

DRUG2 trials

Sponsors

Amgen

Conditions

Low Bone Mineral DensityPostmenopausal OsteoporosisPostmenopausal Women With Osteoporosis

Phase 2

Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density

CompletedNCT00896532

AmgenLow Bone Mineral Density, Postmenopausal Osteoporosis

Start: 2009-06-03End: 2016-02-18Updated: 2022-09-22

Phase 3

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

CompletedNCT01631214

AmgenPostmenopausal Women With Osteoporosis

Start: 2012-05-04End: 2017-06-29Updated: 2025-02-21

Related Papers

Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes.

2025-09-01

Romosozumab significantly improves vertebral cortical bone mass and structure compared with teriparatide, whereas both treatments increase vertebral trabecular bone mass similarly: high-resolution quantitative computed tomography analyses of randomized controlled trial results in postmenopausal women with low bone mineral density

JBMR Plus2025-07-151 citations

Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.

2024-04-044 citations

Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study

JBMR Plus2024-01-274 citations

Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.

2021-09-2014 citations

Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Journal of Bone and Mineral Research2021-07-0167 citations

Skeletal responses to romosozumab after 12 months of denosumab

JBMR Plus2021-05-1469 citations

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Regulatory Toxicology and Pharmacology2020-06-2346 citations

<i>T</i>-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial

Journal of Bone and Mineral Research2020-05-2251 citations

Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide

Journal of Bone and Mineral Research2020-04-0121 citations

T-score as an Indicator of Fracture Risk on Therapy: Evidence From Romosozumab vs Alendronate Treatment in the ARCH Trial

Osteologie/Osteology2020-02-013 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

Journal of Bone and Mineral Research2018-04-25223 citations

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

New England Journal of Medicine2017-09-111377 citations

Romosozumab in Postmenopausal Women with Low Bone Mineral Density

New England Journal of Medicine2014-01-011203 citations